Plain-English translation of NCT07096934 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new treatment called CYWC628, which is made from human skin cells grown in the lab, to see if it can help heal diabetic foot ulcers that haven't gotten better with standard care alone. You would receive either standard wound care alone, or standard care plus the new medication at one of two doses, applied once a week for up to 12 weeks. The study wants to find out if this treatment is safe and whether it helps wounds heal better than standard care by itself.
Diabetic foot ulcers can be very difficult to heal and may lead to serious complications. This medication offers a new approach using specially grown skin cells that might help wounds heal faster and reduce the risk of infection or amputation.
You likely qualify if…
You likely don't qualify if…
You would come to a clinic once a week for up to 12 weeks. At each visit, your wound would be cleaned and assessed, measurements and photos would be taken to track healing, and you would receive your assigned treatment (either standard care alone or standard care plus the new medication applied directly to the wound). You'll also have vital signs checked and blood tests done. The entire treatment period lasts up to 12 weeks, though your participation could end earlier if your wound heals completely.
AI-generated summary from trial data · Sep 20, 2026 · Not medical advice
Australia